Eli Lilly and Company LLY
$1112.09▼ -2.41% 24H
Super Investor & Insider
6
Fondi che lo detengono
#102
Rank consenso
8.6%
% dei portafogli
$1.39B
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Polen Capital Management · Polen Capital Management | 5.82% | Reduce 26.61% | 914,557 | $841.2M |
| Mairs & Power · Mairs & Power | 3.07% | Reduce 5.51% | 326,306 | $300.1M |
| Jensen Investment Management · Jensen Investment Management | 4.18% | Reduce 7.67% | 230,671 | $212.2M |
| Dodge & Cox · Dodge & Cox | 0.02% | Reduce 1.13% | 42,012 | $38.6M |
| Bill Nygren · Harris Associates | 0% | Add 8.7% | 450 | $413,897 |
| David Katz · Matrix Asset Advisors | 0.03% | Reduce 4.31% | 311 | $285,592 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Headquartered in Indianapolis, Indiana, the company focuses on therapies addressing diabetes, oncology, immunology, neuroscience, and cardiometabolic conditions. Its portfolio includes me…
SectorHealthcare
ExchangeNYSE
IndustryDrug Manufacturers - General
CountryUnited States
Employees50,000
TickerLLY
Statistics
Market Cap$993.65B
Revenue (TTM)$65.18B
Net Income$20.64B
Net Margin31.7%
EPS$22.95
P/E41.33
P/S14.33
P/B33.25
EV/EBITDA29.64
ROE107.5%
Dividend Yield0.60%
Price$1112.09
Data: Twelve Data · Revenue = mcap / P/S